Connect
← Return to Something new in the treatment arsenal?
Discussion
Something new in the treatment arsenal?
Breast Cancer | Last Active: Aug 7 11:34am | Replies (61)Comment receiving replies
Unfortunately, I have no additional information as this announcement was from a financial resource rather than health care site. I do follow the ASCO post online and under the News heading, it does show FDA approval for 4 new treatments and details for use. The more we know helps us sort thru decisions for the future. Hope this helps a bit.
Replies to "Unfortunately, I have no additional information as this announcement was from a financial resource rather than..."
Hello, I am in Montreal and I am in Phase 3 of the trial you are talking about.
The trial is called Tropion 01 for HR+ HER2 - (or low). I started Nov 1, 2022.
To qualify you have to be stage 4 and have already tried a few other lines of treatment. I had been on Kisqali, Afinitor, and Xeloda prior to this trial.
When I started the trial, I had a tumour in my left breast, several lymph nodes under my left arm were impacted, and I had Mets in my hips, my lower spine, my sixth rib, one of my vertebrae‘s and my sternum. Currently the only cancer that can be seen on The CT scan is in three of my lymph nodes, which is significantly smaller.
I imagine we will be hearing more talk about this at the San Antonio symposiu
I have HR+ HER2- mbc and had been on Verzenio for 6 months then Abraxane chemo for 6 months before each began losing effectiveness. My oncologist is prescribing a newly approved immunotherapy pill called Truqap produced by AstraZenica. I have not started this treatment yet but reading indicates side effects similar to Verzenio et al. My oncologist said Truqap is not in the same family as Verzenio et al though. As a side note, I was also in a Kisqali trial during 2019-2020 before losing my eyesight to corneal damage caused by bacterial infections in each eye 6 months apart (I add this to warn users to be aware of any eye sensitivity and see your optometrist immediately). Here is a link to more information on Truqap https://www.astrazeneca.com/media-centre/press-releases/2023/truqap-approved-in-us-for-hr-plus-breast-cancer.html
Connect
@nlb122 thanks for sharing!
I just looked it up and it's for HR+ HER2 low or negative breast cancer. They also had similar results with it for non-small cell lung cancer. Sounds promising for lots of people. I didn't see any actual data so I wonder how is compares to PFS time achieved with Kisqali, Ibrance and Verzenio? If anyone sees the progression free survival (PFS) time posted, please post here. Thanks!